Intravascular Ultrasound-Guided PCI in Patients With Chronic Kidney Disease

Prior treatment

• PCI within the previous 12 months
• Current intake of nephrotoxic medications (e.g., nonsteroidal anti-inflammatory drugs except acetylsalicylic acid, phenylbutazone, aminoglycosides, amphotericin B, polymyxin, platinum complexes)
• Planned exposure to contrast within 72 h after the procedure, intravascular administration of contrast within the previous 5 days

Other illness

• Target lesion of stent thrombosis or in-stent restenosis
• Any planned non-cardiac surgery within 12 months
• History of intracranial or gastrointestinal bleeding requiring transfusion or surgical intervention for control (excluding hemorrhoid)
• Immune-related kidney disease or on hormone therapy (e.g. lupus nephritis, IgA nephropathy)
• Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial
• Patients allergic to metals or contrast

Lab values

• LVEF ≤ 30%
• Severe hepatic dysfunction, defined as ALT or AST more than 5 times the ULN
• Contraindication to anti-platelet agents
• Hemoglobin \<60 g/L

Other

• Onset of STEMI within 24 hours or emergent angiography
• Pregnant or childbearing women
• Co-morbidity with an estimated life expectancy of \< 1 year
• Cardiogenic shock or hemodynamic instability
• Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk
• Current enrolment in other clinical trials
• Chronic total occlusion lesion with unsuccessful guidewire crossing
• Intake of anticoagulants

• CKD patients with eGFR\<60 mL/min/1.73 m\^2
• De novo coronary lesion suitable for second-generation metallic drug-eluting stent placement and IVUS imaging
• Signed written informed consent